Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance - PubMed (original) (raw)
Review
. 2009 Mar-Apr;87(3):195-202.
doi: 10.1038/icb.2008.106. Epub 2009 Jan 27.
Affiliations
- PMID: 19172156
- DOI: 10.1038/icb.2008.106
Review
Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance
Liqing Wang et al. Immunol Cell Biol. 2009 Mar-Apr.
Abstract
The histone/protein deacetylase inhibitor (HDACi), trichostatin A (TsA), increases the production and suppressive function of Foxp3(+) regulatory T cells (T(regs)), at least in part, by promoting the acetylation of Foxp3 protein itself. Acetylation of Foxp3 is required for effective binding of Foxp3 to the promoter of the interleukin-2 (IL-2) gene and the suppression of IL-2 expression. We have sought to identify agents that had similar effects on T(regs), but without the associated toxicity of TsA. This review summarizes the contrasting effects of various HDACis on T(reg) functions in vitro and in vivo. Agents that block primarily class I HDAC had minimal or no effect on T(reg) suppression, whereas multiple inhibitors of both class I and class II HDAC enhanced T(reg) suppression in vitro and in vivo. These data indicate tools for further analysis of T(reg) functions, and point to a critical role of class II HDAC in the regulation of T(regs). Such knowledge has direct implications for the development of in vivo approaches to treat autoimmune and other inflammatory diseases.
Similar articles
- Deacetylase inhibition promotes the generation and function of regulatory T cells.
Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, Li B, Turka LA, Olson EN, Greene MI, Wells AD, Hancock WW. Tao R, et al. Nat Med. 2007 Nov;13(11):1299-307. doi: 10.1038/nm1652. Epub 2007 Oct 7. Nat Med. 2007. PMID: 17922010 - Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms.
Beier UH, Wang L, Han R, Akimova T, Liu Y, Hancock WW. Beier UH, et al. Sci Signal. 2012 Jun 19;5(229):ra45. doi: 10.1126/scisignal.2002873. Sci Signal. 2012. PMID: 22715468 Free PMC article. - Deacetylase inhibitor trichostatin A down-regulates Foxp3 expression and reduces CD4+CD25+ regulatory T cells.
Liu Z, Zhang C, Sun J. Liu Z, et al. Biochem Biophys Res Commun. 2010 Sep 24;400(3):409-12. doi: 10.1016/j.bbrc.2010.08.090. Epub 2010 Aug 27. Biochem Biophys Res Commun. 2010. PMID: 20801101 - Rationale for HDAC inhibitor therapy in autoimmunity and transplantation.
Hancock WW. Hancock WW. Handb Exp Pharmacol. 2011;206:103-23. doi: 10.1007/978-3-642-21631-2_6. Handb Exp Pharmacol. 2011. PMID: 21879448 Review. - Histone deacetylase inhibitors and transplantation.
Tao R, de Zoeten EF, Ozkaynak E, Wang L, Li B, Greene MI, Wells AD, Hancock WW. Tao R, et al. Curr Opin Immunol. 2007 Oct;19(5):589-95. doi: 10.1016/j.coi.2007.07.015. Epub 2007 Aug 24. Curr Opin Immunol. 2007. PMID: 17719760 Free PMC article. Review.
Cited by
- Class-specific histone/protein deacetylase inhibition protects against renal ischemia reperfusion injury and fibrosis formation.
Levine MH, Wang Z, Bhatti TR, Wang Y, Aufhauser DD, McNeal S, Liu Y, Cheraghlou S, Han R, Wang L, Hancock WW. Levine MH, et al. Am J Transplant. 2015 Apr;15(4):965-73. doi: 10.1111/ajt.13106. Epub 2015 Feb 23. Am J Transplant. 2015. PMID: 25708614 Free PMC article. - Histone deacetylase inhibitors: a new and promising drug class for the treatment of arthritis?
Toussirot E, Khan KA, Herbein G. Toussirot E, et al. Clin Epigenetics. 2010 Sep;1(1-2):3-6. doi: 10.1007/s13148-010-0002-6. Epub 2010 May 29. Clin Epigenetics. 2010. PMID: 22704084 Free PMC article. No abstract available. - Epigenetic mechanisms of regulation of Foxp3 expression.
Lal G, Bromberg JS. Lal G, et al. Blood. 2009 Oct 29;114(18):3727-35. doi: 10.1182/blood-2009-05-219584. Epub 2009 Jul 29. Blood. 2009. PMID: 19641188 Free PMC article. Review. - HDAC11, an emerging therapeutic target for metabolic disorders.
Chen H, Xie C, Chen Q, Zhuang S. Chen H, et al. Front Endocrinol (Lausanne). 2022 Oct 20;13:989305. doi: 10.3389/fendo.2022.989305. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36339432 Free PMC article. Review. - Epigenetic modifications in brain and immune cells of multiple sclerosis patients.
Castro K, Casaccia P. Castro K, et al. Mult Scler. 2018 Jan;24(1):69-74. doi: 10.1177/1352458517737389. Mult Scler. 2018. PMID: 29307300 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials